Home Newsfeeds Maxim Group Downgrades Pulse Biosciences to Hold

Maxim Group Downgrades Pulse Biosciences to Hold

Maxim Group analyst Anthony Vendetti downgrades Pulse Biosciences (NASDAQ:PLSE) from Buy to Hold.

byBenzinga Newsdesk

September 21, 2022

1 minute read

Maxim Group analyst Anthony Vendetti downgrades Pulse Biosciences (NASDAQ:PLSE) from Buy to Hold.

Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $408

By Benzinga Newsdesk

October 12, 10:05 AM

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $412 to $408.

LLY

Citigroup Maintains Neutral on Trinseo, Raises Price Target to $29

By Benzinga Newsdesk

January 31, 8:52 AM

Citigroup analyst PJ Juvekar maintains Trinseo (NYSE:TSE) with a Neutral and raises the price target from $27 to $29.

TSE

Discover Financial Q4 EPS $3.77 Beats $3.66 Estimate, Sales $3.73B Beat $3.66B Estimate

By Michael Horton

January 18, 5:19 PM

Discover Financial (NYSE:DFS) reported quarterly earnings of $3.77 per share which beat the analyst consensus estimate of $3.66 by 3.01 percent. This is a 3.57 percent increase over earnings of $3.64 per share from the

DFS

Baozun Beats Revenue Estimates with Strong Q1 Growth, Shares Surge

By Anusuya Lahiri

May 28, 7:33 AM

Baozun reported Q1 2024 revenue growth of 4.9%, beating analyst estimates. Adjusted EPS loss was $0.03. Stock price gained. Services revenue up 4.1%. Cash and equivalents at $408.1M. Baozun making progress in E-commerce and Brand Management. Stock lost 32% in past year.

BZUN

Maxim Group Downgrades Pulse Biosciences to Hold

Related Posts

Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $408

Citigroup Maintains Neutral on Trinseo, Raises Price Target to $29

Discover Financial Q4 EPS $3.77 Beats $3.66 Estimate, Sales $3.73B Beat $3.66B Estimate

Baozun Beats Revenue Estimates with Strong Q1 Growth, Shares Surge